Managing malignant melanoma

Plastic and Reconstructive Surgery

Volumn 132, Issue 3, 2013, Pages

  Dzwierzynski, William W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; CANCER STAGING; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; PATHOLOGY; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SKIN; SKIN NEOPLASMS; REVIEW; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; BIOPSY; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN; SKIN NEOPLASMS;

EID: 84883594298     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31829ad411     Document Type: Article

References (53)

1. Siegel R, Ward E, Brawley O., Jemal A. Cancer Statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
2. Ivry GB, Ogle CA, Shim EK Role of sun exposure in melanoma. Dermatol Surg. 2006; 32: 481-492.
3. Forman SB, Ferringer TC, Peckham S.J., et al. Is superficial spreading melanoma still the most common form of malignant melanoma? J Am Acad Dermatol. 2008; 58: 1013-1020.
4. Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol. 2006; 19(SUPPL. 2):S34-S40.
5. McGuire LK, Disa JJ, Lee E.H., Busam KJ, Nehal KS. Melanoma of the lentigo maligna subtype: Diagnostic challenges and current treatment paradigms. Plast Reconstr Surg. 2012; 129: 288e-299e.
6. Bradford PT, Goldstein AM, McMaster M.L., Tucker MA. Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009; 145: 427-434.
7. Chen JY, Hruby G, Scolyer R.A., et al. Desmoplastic neurotropic melanoma: A clinicopathologic analysis of 128 cases. Cancer 2008; 113: 2770-2778.
8. Pflugfelder A, Weide B, Eigentler T.K., et al. Incisional biopsy and melanoma prognosis: Facts and controversies. Clin Dermatol. 2010; 28: 316-318.
9. Martin RC I.I., Scoggins CR, Ross M.I., et al. Is incisional biopsy of melanoma harmful? Am J Surg. 2005; 190: 913-917.
10. Paek SC, Griffith KA, Johnson T.M., et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-108.
11. Coit DG, Andtbacka R, Bichakjian C.K., et al.; NCCN Melanoma Panel. Melanoma. J Natl Compr Canc Netw. 2009; 7: 250-275.
12. Gershenwald JE, Soong SJ, Balch CM; American Joint Committee on Cancer (AJCC) Melanoma Staging Committee. 2010 TNM staging system for cutaneous melanoma⋯ and beyond. Ann Surg Oncol. 2010; 17: 1475-1477.
13. Barnhill RL, Katzen J, Spatz A., Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005; 32: 268-273.
14. Balch CM, Gershenwald JE, Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-6206.
15. Balch CM, Soong SJ, Smith T, et al; Investigators from the Intergroup Melanoma Surgical Trial. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001; 8: 101-108.
16. Thomas JM, Newton-Bishop J, A'Hern R, et al.; United Kingdom Melanoma Study Group; British Association of Plastic Surgeons; Scottish Cancer Therapy Network. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004; 350: 757-766.
17. Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma: Updated pooled analysis of randomized controlled trials. Arch Surg. 2007; 142: 885-891; discussion 891.
18. Sladden MJ, Balch C, Barzilai D.A., et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009; 4:CD004835.
19. Johnson TM, Headington JT, Baker S.R., Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: The "square," procedure. J Am Acad Dermatol. 1997; 37: 758-764.
20. Bosbous MW, Dzwierzynski WW, Neuburg M. Lentigo maligna: Diagnosis and treatment. Clin Plast Surg. 2010; 37: 35-46.
21. O'Connor E.A., Dzwierzynski W. Longitudinal melonychia: Clinical evaluation and biopsy technique. J Hand Surg Am. 2011; 36: 1852-1854.
22. Moxley KM, Fader AN, Rose P.G., et al. Malignant melanoma of the vulva: An extension of cutaneous melanoma? Gynecol Oncol. 2011; 122: 612-617.
23. Zitelli JA, Brown C, Hanusa BH Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 1997; 37: 236-245.
24. Hochwald SN, Coit DG Role of elective lymph node dissection in melanoma. Semin Surg Oncol. 1998; 14: 276-282.
25. Coates AS, Ingvar CI, Petersen-Schaefer K, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. J Am Coll Surg. 1995; 180: 402-409.
26. Drepper H, Köhler CO, Bastian B., et al. Benefit of elective lymph node dissection in subgroups of melanoma patients: Results of a multicenter study of 3616 patients. Cancer 1993; 72: 741-749.
27. Elder DE, Guerry D IV, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985; 56: 413-418.
28. Cigna E, Gradilone A, Ribuffo D., et al. Morbidity of selective lymph node biopsy for melanoma: Meta-analysis of complications. Tumori 2012; 98: 94-98.
29. de Vries M., Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol. 2006; 32: 785-789.
30. Wrightson WR, Wong SL, Edwards M.J., et al.; Sunbelt Melanoma Trial Study Group. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003; 10: 676-680.
31. Wagner JD. Lymphatic mapping and sentinel lymph node basin after sentinel lymph node biopsy for melanoma. Plast Reconstr Surg. 2000; 106: 515-516.
32. Morton DL, Cochran AJ, Thompson J.F., et al.; Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005; 242: 302-311; discussion 311.
33. Thompson JF, Shaw HM Sentinel node mapping for melanoma: Results of trials and current applications. Surg Oncol Clin North Am. 2007; 16: 35-54.
34. Wong SL, Brady MS, Busam K.J., Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006; 13: 302-309.
35. Ferrone CR, Panageas KS, Busam K, Brady M.S., Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: Importance of sentinel lymph node status. Ann Surg Oncol. 2002; 9: 637-645.
36. Stadelmann WK. The role of lymphatic mapping and sentinel lymph node biopsy in the staging and treatment of melanoma. Clin Plast Surg. 2010; 37: 79-99.
37. Ohsie SJ, Sarantopoulos GP, Cochran A.J., Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008; 35: 433-444.
38. Shidham VB, Chang CC, Komorowski R. MCW melanoma cocktail for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma. Expert Rev Mol Diagn. 2005; 5: 281-290.
39. Miranda EP, Gertner M, Wall J., et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg. 2004; 139: 831-836; discussion 836.
40. Morton RL, Craig JC, Thompson JF The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol. 2009; 16: 571-577.
41. Dzwierzynski WW. Complete lymph node dissection for regional nodal metastasis. Clin Plast Surg. 2010; 37: 113-125.
42. Morton DL, Thompson JF, Cochran A.J., et al.; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006; 355: 1307-1317.
43. Cascinelli N, Belli F, MacKie R.M., Santinami M., Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001; 358: 866-869.
44. Kirkwood JM, Ibrahim JG, Sondak V.K., et al. High- and lowdose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 2444-2458.
45. Verma S, Quirt I, McCready D., Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 1431-1442.
46. Eggermont AM, Suciu S, Santinami M., et al.; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.
47. Yao KA, Hsueh EC, Essner R, Foshag L.J., Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 2003; 238: 743-747.
48. Beasley GM, Caudle A, Petersen R.P., et al. A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg. 2009; 208: 706-715; discussion 715.
49. Serrone L, Zeuli M, Sega F.M., Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res. 2000; 19: 21-34.
50. Hodi FS, O'Day SJ, McDermott DF, et al Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
51. Chapman PB, Hauschild A, Robert C., et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
52. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007; 25: 5426-5434.
53. Hornyak TJ. Future advances in melanoma research. Clin Plast Surg. 2010; 37: 169-176.